Dergiler / Molecular Imaging and Radionuclide Therapy / 2013 / Cilt: 22 - Sayı: 2
18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnosis and Post-Therapeutic Treatment in a Patient with an Early Stage of Retroperitoneal Fibrosis
- Sayfa
- 60–62
- DOI
- —
Özet
Erken dönemde bir Idyopatik Retroperitoneal Fibrosis (IRF) hastasında yapılan 18F-FDG-PET/BT deneyimini sunduk. Tanı amaçlı Kontrastlı Bilgisayarlı Tomografide (CE-CT) infrarenal bölgede periaortik solid doku ve lokal-bölgesel lenf nodları görüldü ve lenfatik doku olarak yorumlandı. 18F-FDG-PET/BT periaortik dokuda artmış 18F-FDG tutulumu gösterdi ama lenf nodlarında hiç tutulum yoktu. Histolojik inceleme başlangıç aşamasında IRF olarak geldi. Tedavinin sonuna yakın, CE-CT fibröz dokuda artış ve 18F-FDG-PET/BT önceki bahsedilen lezyonda ve de aort duvarındaki başka bir lezyonda artmış 18F-FDG tutulumu görüldü. 18F-FDG-PET/BT, klinik olarak şüpheli bulunan retroperitoneal fibrosis vakalarının tanı ve yönlendirilmesinde önemli rol oynayabilir. Daha sonra hastaya methotrexate tedavisi başlandı ve altı ay sonra yapılan 18F-FDG-PET/BT de 18F-FDG tutulumu izlenmedi.
Abstract
Here, we report an experience about 18F-FDG-PET/CT in a patient with an early stage of Idiopathic Retroperitoneal Fibrosis (IRF). At the diagnosis Contrast Enhanced Computed Tomography (CE-CT) revealed periaortic solid tissue in the infrarenal section and locoregional lymph nodes; findings were interpreted as lymphomatous tissue. 18F-FDG-PET/CT showed elevated 18F-FDG uptake in the periaortic tissue but no uptake was detected in lymph nodes. The histologic examination showed recent-onset IRF. The patient began corticosteroid therapy. Nearly at the end of the therapy, CE-CT showed the enlargement of the fibrous tissue and 18F-FDG-PET/CT showed an increased 18F-FDG uptake in the aforesaid lesion and another area of uptake in the aortic wall. 18F-FDG-PET/CT can play an important role in the diagnosis of patients with an initial clinical suspicion of retroperitoneal fibrosis and in their management. Then the patient began a therapy with methotrexate and after six months we performed an 18F-FDG-PET/CT which didnt show 18F-FDG uptake.